NO20084872L - 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig - Google Patents

2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig

Info

Publication number
NO20084872L
NO20084872L NO20084872A NO20084872A NO20084872L NO 20084872 L NO20084872 L NO 20084872L NO 20084872 A NO20084872 A NO 20084872A NO 20084872 A NO20084872 A NO 20084872A NO 20084872 L NO20084872 L NO 20084872L
Authority
NO
Norway
Prior art keywords
treatment
neutrophil elastase
inhibition
disease
beneficial
Prior art date
Application number
NO20084872A
Other languages
English (en)
Inventor
Matti Lepisto
Peter Hansen
Hans Lonn
Karolina Lawitz
Asim Ray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084872(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084872L publication Critical patent/NO20084872L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Foreliggende oppfinnelsen tilveiebringer forbindelser med formel hvori R1, R3, R4, R5, R6, R14, X og W er som definert i beskrivelsen og optiske isomerer, racemater og tautomerer derav, og farmasøytisk akseptable salter derav; sammen med frerngangsmåter for deres fremstilling, farmasøytiske sammensetninger som inneholder dem og deres anvendelse ved behandling. Forbindelsene er inhibitorer av human neutrofil elastase.
NO20084872A 2006-05-08 2008-11-19 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig NO20084872L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79878606P 2006-05-08 2006-05-08
PCT/SE2007/000441 WO2007129962A1 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.

Publications (1)

Publication Number Publication Date
NO20084872L true NO20084872L (no) 2009-02-03

Family

ID=38667997

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084872A NO20084872L (no) 2006-05-08 2008-11-19 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig

Country Status (20)

Country Link
US (1) US7998984B2 (no)
EP (1) EP2018375B1 (no)
JP (1) JP2009536196A (no)
KR (1) KR20090017573A (no)
CN (1) CN101490033A (no)
AR (1) AR060875A1 (no)
AT (1) ATE459615T1 (no)
AU (1) AU2007248950B2 (no)
BR (1) BRPI0711357A2 (no)
CA (1) CA2649813A1 (no)
CL (1) CL2007001282A1 (no)
DE (1) DE602007005120D1 (no)
ES (1) ES2339607T3 (no)
IL (1) IL194948A0 (no)
MX (1) MX2008013836A (no)
NO (1) NO20084872L (no)
TW (1) TW200808763A (no)
UY (1) UY30328A1 (no)
WO (1) WO2007129962A1 (no)
ZA (1) ZA200809024B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
PL2066662T3 (pl) * 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
WO2009061271A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2508189A3 (de) * 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
CA2773618A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
JP2013177318A (ja) * 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9409870B2 (en) * 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
HK1249504A1 (zh) 2015-09-02 2018-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited 用作溴结构域抑制剂的吡啶酮二甲酰胺
CN106674098B (zh) * 2016-12-23 2019-07-02 中国医科大学 N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN114650819A (zh) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
EP4419102A1 (en) 2021-10-20 2024-08-28 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
ES2330719T3 (es) * 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
BR0211900A (pt) * 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
PT1477186E (pt) * 2002-02-19 2010-02-11 Shionogi & Co Antipruriginosos
JP4619122B2 (ja) 2002-08-27 2011-01-26 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｈｎｅインヒビターとしてのジヒドロピリジノン誘導体
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP5134248B2 (ja) 2004-02-19 2013-01-30 バイエル・ファルマ・アクチェンゲゼルシャフト ジヒドロピリジノン誘導体
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR200365249Y1 (ko) * 2004-07-28 2004-10-21 추윤정 전동 퍼프
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
NZ572250A (en) 2006-05-04 2011-10-28 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009061271A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
KR20090017573A (ko) 2009-02-18
BRPI0711357A2 (pt) 2011-09-27
US7998984B2 (en) 2011-08-16
AR060875A1 (es) 2008-07-16
AU2007248950A1 (en) 2007-11-15
AU2007248950B2 (en) 2010-11-18
JP2009536196A (ja) 2009-10-08
ZA200809024B (en) 2010-03-31
CN101490033A (zh) 2009-07-22
ES2339607T3 (es) 2010-05-21
DE602007005120D1 (de) 2010-04-15
CA2649813A1 (en) 2007-11-15
UY30328A1 (es) 2008-01-02
WO2007129962A1 (en) 2007-11-15
ATE459615T1 (de) 2010-03-15
HK1127599A1 (en) 2009-10-02
EP2018375A1 (en) 2009-01-28
TW200808763A (en) 2008-02-16
US20090131486A1 (en) 2009-05-21
MX2008013836A (es) 2008-11-10
IL194948A0 (en) 2009-08-03
CL2007001282A1 (es) 2008-01-18
EP2018375B1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20061700L (no) 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse
NO20074274L (no) Tetrahydroindolon og tetrahydroindazolonderivater
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
NO20061660L (no) 2-pyridonderivate som neutrofil elasaeinhibitor og deres anvendelse
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application